Showing posts with label Respiratory. Show all posts
Showing posts with label Respiratory. Show all posts

Saturday, September 28, 2013

0 Human Respiratory Syncytial Virus Infection

Human Respiratory Syncytial Virus Infection


Edited by Bernhard Resch, ISBN 978-953-307-718-5, Hard cover, 246 pages, Publisher: InTech, Published: November 25, 2011 under CC BY 3.0 license, in subject Infectious Diseases
DOI: 10.5772/1496





In this online Open Access book on “Human RSV Infections”, several distinguished authors contribute their experience in respiratory syncytial virology. A major focus lies on the fascinating pathophysiology of RSV and represents recent and actual work on different mechanisms involved in the complex pathogenesis of the virus. The second section elucidates epidemiologic and diagnostic aspects of RSV infection covering a more clinical view of RSV disease. At last, treatment modalities including the search for a vaccine that is still not in sight are discussed and conclude this book, thus building up a circle that runs from experimental models of RSV related lung disease over clinical aspects of disease to the latest news of therapeutic and prophylactic approaches to human RSV infection.

This book is indexed in:


Worldcat Base AZ ebsco Scirus Google Scholar



BOOK CONTENTS




Sunday, September 15, 2013

0 Tolerability to Etoricoxib in Patients With Aspirin-Exacerbated Respiratory Disease






























Original Article

 

Tolerability to Etoricoxib in Patients With Aspirin-Exacerbated Respiratory Disease

 

D Koschel,1 C Ninck Weber,1 G Höffken1,2


1Department of Pulmonary Diseases, Fachkrankenhaus Coswig, Centre for Pulmonary Diseases and Thoracic Surgery, Coswig, Germany
2Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany



J Investig Allergol Clin Immunol 2013; Vol. 23(4): 275-280

 















 Abstract







Background: The use of selective cyclooxygenase (COX) 2 inhibitors as an alternative to aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has been suggested for patients with aspirin-exacerbated respiratory disease (AERD).

Objective: To evaluate tolerability to etoricoxib, a second-generation COX-2 inhibitor with high in vitro selectivity for COX-2 in patients with AERD.


Methods: We conducted a retrospective review of patients with suspected aspirin intolerance seen between October 2007 and April 2012. Single-blind, placebo-controlled oral challenges with increasing doses of aspirin and etoricoxib were performed on 3 different days.


Results: Of 262 patients with suspected aspirin intolerance, 248 underwent challenge testing with aspirin and 122 (49.2%) showed positive test results. In 104 of these aspirin-sensitive patients, etoricoxib was tested as an alternative drug and was tolerated in all but 3 (2.9%), who developed a positive asthmatic reaction.


Conclusions: The highly selective COX-2 inhibitor etoricoxib was tolerated in most but not all patients tested. An oral provocation test is therefore recommended before prescribing etoricoxib for patients with AERD.


Key words: Aspirin-exacerbated respiratory disease. Asthma. COX-II inhibitor. Etoricoxib. Hypersensitivity







Â